Proactive Investors - Run By Investors For Investors

Silence Therapeutics makes key new hire

Giles Campion has been appointed head of research and development and chief medical officer
Silence Therapeutics makes key new hire
Chief executive David Horn Solomon said Campion would be a valuable addition to the management team

Silence Therapeutics PLC (LON:SLN) has appointed industry veteran Giles Campion as head of research and development and the company’s chief medical officer.

He occupied the same roles at Prosensa, which was acquired by Biomarin in 2015 for US$680mln and, in his 20-year career, he also held senior R&D roles at the Swiss giant Novartis (NYSE:NVS). He holds a medical degree and doctorate from Bristol University.

READ: Silence Therapeutics makes clinical trial application for lead drug

“Giles is a valuable addition to the management team and his expertise will help the company to deliver on its core mission of tackling the unmet medical needs of patients suffering from rare conditions," said Silence chief executive David Horn Solomon.

Campion joins the company on June 1

In a later announcement, Silence also said the search for a permanent chairman continues after announcing that interim chair, Dr Andy Richards, had stepped down with immediate effect.

 -- Adds chairman's departure --

View full SLN profile View Profile

Silence Therapeutics PLC Timeline

Related Articles

Cancer cells
February 06 2019
In October 2018, Maxcyte saw the first patient dosed in an initial phase I trial using its lead MCY-M11 therapy, tracking a total of 15 women with relapsed or hard-to-treat forms of cancer
1550850611_CancerHeadline.jpg
February 22 2019
Broker Hybridan reckons Sareum is “arguably a bargain target for the relatively large group of biotech and pharma companies interested in TYK2 and the wider JAK inhibitor space”
seeds in a bowl
March 07 2019
The Vancouver company is developing Omega-3 products as oil, powder or emulsion to be used as food additives

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use